[PDF][PDF] A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

A Tauzin, M Nayrac, M Benlarbi, SY Gong, R Gasser… - Cell host & …, 2021 - cell.com
While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses, …

[PDF][PDF] Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike

…, A Laumaea, SP Anand, G Goyette, M Benlarbi… - Cell Reports …, 2020 - cell.com
SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting
millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins …

[PDF][PDF] Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

…, M Nayrac, G Beaudoin-Bussières, M Benlarbi… - Cell Reports …, 2021 - cell.com
With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines,
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-…

[PDF][PDF] Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

…, G Beaudoin-Bussières, K Symmes, M Benlarbi… - Immunity, 2021 - cell.com
Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of
immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) …

[PDF][PDF] A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

…, J Prévost, WD Tolbert, K Symmes, S Ding, M Benlarbi… - Cell reports, 2022 - cell.com
Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of
antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector …

[PDF][PDF] Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

…, D Vézina, R Gasser, L Nault, L Marchitto, M Benlarbi… - Cell host & …, 2022 - cell.com
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

[PDF][PDF] Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

A Tauzin, A Nicolas, S Ding, M Benlarbi, H Medjahed… - Cell Reports, 2023 - cell.com
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants
have recently emerged, becoming the dominant circulating strains in many countries. …

[HTML][HTML] Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2

…, D Adam, NG Vergara, A Tauzin, M Benlarbi… - Journal of Biological …, 2021 - ASBMB
The seasonal nature of outbreaks of respiratory viral infections with increased transmission
during low temperatures has been well established. Accordingly, temperature has been …

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality

…, A Pagliuzza, R Gasser, M Benlarbi… - Science …, 2021 - science.org
Despite advances in COVID-19 management, identifying patients evolving toward death
remains challenging. To identify early predictors of mortality within 60 days of symptom onset (…

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis

R Goupil, M Benlarbi, W Beaubien-Souligny… - Cmaj, 2021 - Can Med Assoc
BACKGROUND: Patients receiving in-centre hemodialysis are at high risk of exposure to
SARS-CoV-2 and death if infected. One dose of the BNT162b2 SARS-CoV-2 vaccine is …